Chimeric antigen receptor T-cell therapy for multiple myeloma

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) is an incurable plasma cell malignancy driven by clonal evolution, leading to treatment resistance.
• Advances in adoptive T cell therapy, particularly chimeric antigen receptor T-cell (CAR-T) therapy, have improved outcomes but face challenges.
• Relapsed/refractory multiple myeloma (RRMM) presents significant prognostic challenges due to its heterogeneity.

Purpose of the Study:

• To review novel tumor-associated neoantigens for MM.
• To summarize current MM CAR-T clinical trial data.
• To explore mechanisms of resistance and relapse post-CAR-T therapy.

Main Methods:

• Literature review of current MM CAR-T clinical trials.
• Analysis of mechanisms underlying CAR-T therapy resistance and relapse.
• Identification of potential novel targets and engineering strategies for CAR-T cells.

Main Results:

• B Cell Maturation Antigen (BCMA) is a key target, with ongoing trials exploring other single and dual targets.
• Mechanisms of resistance include T-cell clearance, antigen escape, and immunosuppressive tumor microenvironment.
• Engineering CAR-T cells aims to enhance efficacy and reduce toxicity.

Conclusions:

• CAR-T therapy offers significant potential for MM treatment, especially for RRMM.
• Addressing durability, toxicity, and resistance mechanisms is crucial for optimizing CAR-T therapy.
• Further research into novel targets, CAR-T cell engineering, and manufacturing processes is needed to improve patient outcomes.